|
|
|
|
LEADER |
01157nam a2200229 u 4500 |
001 |
EB002001037 |
003 |
EBX01000000000000001163938 |
005 |
00000000000000.0 |
007 |
tu||||||||||||||||||||| |
008 |
210907 r ||| eng |
245 |
0 |
0 |
|a Glecaprevir / pibrentasvir (Maviret) (AbbVie corporation)
|h Elektronische Ressource
|
246 |
3 |
1 |
|a CADTH common drug review clinical review report for Maviret
|
260 |
|
|
|a Ottawa (ON)
|b CADTH
|c 2018, February 2018
|
300 |
|
|
|a 1 PDF file (112 pages)
|b illustrations
|
505 |
0 |
|
|a Includes bibliographical references
|
710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
490 |
0 |
|
|a CADTH common drug review clinical review report
|
856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK533768
|3 Volltext
|
082 |
0 |
|
|a 610
|
520 |
|
|
|a The objective of this report was to perform a systematic review of the beneficial and harmful effects of a glecaprevir 100 mg / pibrentasvir 40 mg fixed-dose combination tablet for the treatment of chronic hepatitis C (CHC) genotype 1, 2, 3, 4, 5, and 6 infection in adults
|